Intellia Therapeutics (NTLA) Non-Current Assets (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Non-Current Assets data on file, last reported at $292.3 million in Q1 2026.

• Quarterly Non-Current Assets fell 32.76% year-over-year to $292.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 billion (down 28.13% YoY) and the FY2025 annual result came in at $314.4 million, down 42.95% from the prior year.
• Non-Current Assets declined to $292.3 million in Q1 2026 per NTLA's latest filing, from $314.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $551.2 million in Q4 2024 and bottomed at $215.0 million in Q2 2022.
• The 5-year median for Non-Current Assets is $349.9 million (2023), against an average of $363.1 million.
• Peak annual rise in Non-Current Assets reached 182.73% in 2022, while the deepest fall reached 56.65% in 2022.
• Tracing NTLA's Non-Current Assets over 5 years: stood at $303.3 million in 2022, then slipped by 0.22% to $302.6 million in 2023, then surged by 82.11% to $551.2 million in 2024, then plunged by 42.95% to $314.4 million in 2025, then decreased by 7.02% to $292.3 million in 2026.
• Per Business Quant, the three latest NTLA Non-Current Assets figures stand at $292.3 million (Q1 2026), $314.4 million (Q4 2025), and $343.3 million (Q3 2025).

Peer Comparison